巴曲酶治疗急性脑梗死临床疗效的Meta分析

Effects of Batroxobin on Acute Cerebral Infarction: A Meta-analysis

目的评价巴曲酶治疗急性脑梗死的临床疗效。方法检索有关巴曲酶治疗急性脑梗死的随机对照研究文献。采用Jadad评分评价纳入文献质量。采用RevMan 4.2软件进行Meta分析。结果共有38项研究纳入分析,其中阴性对照29篇,降纤酶对照6篇,尿激酶对照3篇。巴曲酶在有效率、降低神经功能缺损评分、降低纤维蛋白原方面优于阴性对照组(P<0.05),在神经功能缺损评分方面与尿激酶无显著性差异(P>0.05),在有效率方面与降纤酶无显著性差异(P>0.05)。结论巴曲酶可改善急性脑梗死患者神经功能缺损评分,降低纤维蛋白原水平。

Objective To assess the clinical effect of Batroxobin on acute cerebral infarction. Methods Randomized controlled trials （RCTs） about Batroxobin used for acute cerebral infarction were recalled. The quality of the document were assessed with Jadad scale, and the RevMan 4.3 software was used for Meta-analysis. Results 38 RCTs were recalled. 29 trials were negatively controlled, 6 controlled with Defibrase, and 3 controlled with Urokinase. Batroxobin is more effective than negative controls on neurological function score and fibrino- gen （P〈0.05）. There was no statistics difference between Batroxobin and Urokinase on the neurological function score （P〉0.05）, as well as incidence of improvement between Batroxobin and Defibrase （P〉0.05）. Conclusion Batroxobin can effectively improve the neurological function and reduce the fibrinogen for acute cerebral infarction.